22 related articles for article (PubMed ID: 22421777)
1. Third-line pyrotinib, trastuzumab (Zercepac®) and vinorelbine for brain metastases of HER2-positive advanced breast cancer patient.
Wang H; Shao B; DI L
Minerva Med; 2024 Apr; 115(2):257-259. PubMed ID: 35785951
[No Abstract] [Full Text] [Related]
2. [A Long-Surviving Case of Locally Advanced Breast Cancer with Multiple Lung Metastasis].
Satoh E; Innami Y; Uehira D; Yonekura K; Murakata A; Ohinata R; Toyofuku Y; Tanami H; Osanai T; Sugano N; Sakoma T
Gan To Kagaku Ryoho; 2024 Apr; 51(4):427-429. PubMed ID: 38644311
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab response in stage IV luminal-type breast cancer with high microsatellite instability: a case report.
Inakami K; Fujita N; Iguchi C; Enomoto Y; Minohata J; Sata A; Miyagawa Y; Yanagisawa T; Saitoh T; Nomura T; Sawai Y; Takahara K; Kasugai T; Shiba E
J Med Case Rep; 2024 May; 18(1):214. PubMed ID: 38689362
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells.
Shi Y; Zhou F; Jiang F; Lu H; Wang J; Cheng C
Chin J Cancer Res; 2014 Apr; 26(2):142-7. PubMed ID: 24826054
[TBL] [Abstract][Full Text] [Related]
5. Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine.
Asakura H; Takashima H; Mitani M; Haba R; Seo R; Yokoe K; Toyama Y; Ohkawa M
Int J Clin Oncol; 2005 Aug; 10(4):285-8. PubMed ID: 16136377
[TBL] [Abstract][Full Text] [Related]
6. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer.
Lin NU; Seah DS; Gelman R; Desantis S; Mayer EL; Isakoff S; Dipiro P; Krop IE; Come SE; Weckstein D; Winer EP; Burstein HJ
Breast Cancer Res Treat; 2013 Jun; 139(2):403-10. PubMed ID: 23645007
[TBL] [Abstract][Full Text] [Related]
8. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
Burstein HJ; Kuter I; Campos SM; Gelman RS; Tribou L; Parker LM; Manola J; Younger J; Matulonis U; Bunnell CA; Partridge AH; Richardson PG; Clarke K; Shulman LN; Winer EP
J Clin Oncol; 2001 May; 19(10):2722-30. PubMed ID: 11352965
[TBL] [Abstract][Full Text] [Related]
9. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
Burstein HJ; Lieberman G; Slamon DJ; Winer EP; Klein P
Ann Oncol; 2005 Nov; 16(11):1772-7. PubMed ID: 16150805
[TBL] [Abstract][Full Text] [Related]
10. [Remarkable improvement in a patient with metastatic and locally advanced HER2-positive breast cancer treated with trastuzumab plus vinorelbine].
Kanazawa S; Ogata H; Magoshi S; Saito F; Ito T; Kubota Y; Kaneko H
Gan To Kagaku Ryoho; 2012 Mar; 39(3):445-9. PubMed ID: 22421777
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.
Del Mastro L; Lambertini M; Bighin C; Levaggi A; D'Alonzo A; Giraudi S; Pronzato P
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1391-405. PubMed ID: 23072512
[TBL] [Abstract][Full Text] [Related]
12. Pertuzumab in HER2-positive breast cancer.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
